🇺🇸 FDA
Pipeline program

Nerve block with liposomal bupivacaine and intravenous analgesia

KY20230829-05

Approved other active

Quick answer

Nerve block with liposomal bupivacaine and intravenous analgesia for Liposomal Bupivacaine is a Approved program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Liposomal Bupivacaine
Phase
Approved
Modality
other
Status
active

Clinical trials